Surgical Approaches for Prostate Cancer
(PARTIAL Trial)
Trial Summary
What is the purpose of this trial?
This trial compares a new type of prostate cancer surgery to the standard one. The new surgery aims to avoid cutting important tissues and nerves, which might help reduce side effects like urinary problems and sexual dysfunction. The study will see if this new method controls cancer just as well while improving quality of life.
Do I need to stop my current medications for this trial?
The trial information does not specify whether you need to stop taking your current medications.
What data supports the effectiveness of the treatment Pelvic fascia-sparing robot-assisted radical prostatectomy (PFS-RP) for prostate cancer?
Research suggests that preserving the pelvic fascia during robot-assisted radical prostatectomy can lead to faster recovery of urinary function and fewer complications like penile changes and inguinal hernias, without compromising surgical outcomes. However, high-level evidence is still needed to confirm these benefits.12345
Is pelvic fascia-sparing radical prostatectomy safe for humans?
What makes the pelvic fascia-sparing robot-assisted radical prostatectomy (PFS-RP) treatment unique for prostate cancer?
The pelvic fascia-sparing robot-assisted radical prostatectomy (PFS-RP) is unique because it preserves more of the natural structures around the prostate, which may lead to faster recovery of urinary function and fewer complications like penile changes and inguinal hernias compared to conventional robotic-assisted prostatectomy. However, it might have a higher risk of leaving cancerous tissue behind, and more research is needed to confirm these outcomes.23489
Research Team
Jim C Hu, MD, MPH
Principal Investigator
Weill Medical College of Cornell University
Eligibility Criteria
This trial is for men aged 40-80 who are scheduled for prostate cancer surgery, can understand English or Spanish, and agree to follow the study rules. It's not for those with advanced lymph node involvement or a history of major pelvic surgery/radiotherapy.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants undergo either pelvic fascia-sparing radical prostatectomy or standard radical prostatectomy
Follow-up
Participants are monitored for safety and effectiveness after treatment, including assessments of urinary and sexual function, penile shortening, and curvature
Post-surgery Monitoring
Monitoring of biochemical recurrence and surgical margin status
Treatment Details
Interventions
- Pelvic fascia-sparing robot-assisted radical prostatectomy (PFS-RP) (Procedure)
- Robot-assisted radical prostatectomy (RP) (Procedure)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Weill Medical College of Cornell University
Lead Sponsor
Dr. Robert Min
Weill Medical College of Cornell University
Chief Executive Officer since 2024
MD, MBA
Dr. Adam R. Stracher
Weill Medical College of Cornell University
Chief Medical Officer since 2024
MD
National Institutes of Health (NIH)
Collaborator
Dr. Jeanne Marrazzo
National Institutes of Health (NIH)
Chief Medical Officer
MD from University of California, Los Angeles
Dr. Jay Bhattacharya
National Institutes of Health (NIH)
Chief Executive Officer
MD, PhD from Stanford University
National Cancer Institute (NCI)
Collaborator
Dr. Douglas R. Lowy
National Cancer Institute (NCI)
Chief Executive Officer since 2023
MD from New York University School of Medicine
Dr. Monica Bertagnolli
National Cancer Institute (NCI)
Chief Medical Officer since 2022
MD from Harvard Medical School